期刊
ORAL ONCOLOGY
卷 48, 期 11, 页码 1085-1089出版社
ELSEVIER
DOI: 10.1016/j.oraloncology.2012.06.016
关键词
EGFR inhibitor resistance; Head and neck squamous cell carcinoma; ErbB; Aurora kinase; EGFRvIII; PI3K/Akt; MET; VEGF
Head and neck squamous cell carcinoma (HNSCC) affects over half a million people worldwide. Despite advances in therapy, only half of the patients are alive in 5 years. Epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of the tumors, and it is correlated with poor response to treatment and worse outcome. Multiple therapies targeting this pathway have been tested. Cetuximab is the only EGFR inhibitor approved in HNSCC, but response rates are low. More recently, significant interest has focus on identifying mechanisms of acquired and de novo EGFR blockage resistance. Here we review some of these mechanisms and describe strategies to overcome that resistance. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据